امپاگلیفلوزین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "امپاگلیفلوزین" in Persian language version.

refsWebsite

Global rank Persian rank

12nih.gov

4^th place

5^th place

9doi.org

2^nd place

4fda.gov

447^th place

382^nd place

2drugs.com

399^th place

104^th place

2medicines.org.uk

3,823^rd place

1,188^th place

2clincalc.com

3,912^th place

779^th place

1europa.eu

68^th place

179^th place

1worldcat.org

5^th place

12^th place

1nice.org.uk

3,258^th place

1,207^th place

1web.archive.org

1^st place

1va.gov

4,581^st place

6,639^th place

1aafp.org

1,916^th place

580^th place

1who.int

195^th place

129^th place

aafp.org

Zimmermann J (December 2016). "Empagliflozin (Jardiance) for type 2 diabetes mellitus". American Family Physician. 94 (12): 1014–1015. PMID 28075091.

clincalc.com

"The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
"Empagliflozin - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

doi.org

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 61 (12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.
Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James; Verma, Subodh; Tsutsui, Hiroyuki (2020-10-08). "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure". New England Journal of Medicine. 383 (15): 1413–1424. doi:10.1056/NEJMoa2022190. ISSN 0028-4793. PMID 32865377.
Verma S, McMurray JJ (October 2018). "SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review". Diabetologia. 61 (10): 2108–2117. doi:10.1007/s00125-018-4670-7. PMID 30132036.
Anderson JE, Wright EE, Shaefer CF (February 2017). "Empagliflozin: Role in treatment options for patients with type 2 diabetes mellitus". Diabetes Therapy. 8 (1): 33–53. doi:10.1007/s13300-016-0211-x. PMC 5306110. PMID 27837465.
Rosenstock J, Ferrannini E (September 2015). "Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors". Diabetes Care. 38 (9): 1638–1642. doi:10.2337/dc15-1380. PMID 26294774.
Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR (June 2016). "American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis". Endocrine Practice. 22 (6): 753–762. doi:10.4158/EP161292.PS. PMID 27082665.
Abdul-Ghani MA, DeFronzo RA (September 2008). "Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus". Endocrine Practice. 14 (6): 782–790. doi:10.4158/ep.14.6.782. PMID 18996802.
Nair S, Wilding JP (January 2010). "Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus". The Journal of Clinical Endocrinology and Metabolism. 95 (1): 34–42. doi:10.1210/jc.2009-0473. PMID 19892839.
Bays H (March 2009). "From victim to ally: The kidney as an emerging target for the treatment of diabetes mellitus". Current Medical Research and Opinion. 25 (3): 671–681. doi:10.1185/03007990802710422. PMID 19232040.

drugs.com

"Empagliflozin (Jardiance) Use During Pregnancy". Drugs.com. 30 August 2018. Retrieved 10 February 2020.
"Empagliflozin Monograph for Professionals". Drugs.com. AHFS. Retrieved 21 December 2018.

europa.eu

ema.europa.eu

"Jardiance EPAR". European Medicines Agency (EMA). Retrieved 10 February 2020.

fda.gov

"FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 2019-02-09. Retrieved 2019-03-18.
"FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration. 19 March 2020. Retrieved 6 June 2020.

accessdata.fda.gov

"Drug Approval Package: Jardiance (empagliflozin) Tablets NDA #204629". U.S. Food and Drug Administration (FDA). 8 September 2014. Retrieved 10 February 2020.
"Jardiance: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.

medicines.org.uk

"Jardiance 10 mg film-coated tablets – Summary of Product Characteristics (SmPC)". (emc). Retrieved 10 February 2020.
"Jardiance 25 mg film-coated tablets – Summary of Product Characteristics (SmPC)". (emc). 23 October 2019. Retrieved 10 February 2020.

nice.org.uk

"Empagliflozin in combination therapy for treating type 2 diabetes". NICE. Guidance and guidelines. 25 March 2015. Retrieved 21 December 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 61 (12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.
Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James; Verma, Subodh; Tsutsui, Hiroyuki (2020-10-08). "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure". New England Journal of Medicine. 383 (15): 1413–1424. doi:10.1056/NEJMoa2022190. ISSN 0028-4793. PMID 32865377.
Verma S, McMurray JJ (October 2018). "SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review". Diabetologia. 61 (10): 2108–2117. doi:10.1007/s00125-018-4670-7. PMID 30132036.
Zimmermann J (December 2016). "Empagliflozin (Jardiance) for type 2 diabetes mellitus". American Family Physician. 94 (12): 1014–1015. PMID 28075091.
Anderson JE, Wright EE, Shaefer CF (February 2017). "Empagliflozin: Role in treatment options for patients with type 2 diabetes mellitus". Diabetes Therapy. 8 (1): 33–53. doi:10.1007/s13300-016-0211-x. PMC 5306110. PMID 27837465.
Rosenstock J, Ferrannini E (September 2015). "Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors". Diabetes Care. 38 (9): 1638–1642. doi:10.2337/dc15-1380. PMID 26294774.
Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR (June 2016). "American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis". Endocrine Practice. 22 (6): 753–762. doi:10.4158/EP161292.PS. PMID 27082665.
Abdul-Ghani MA, DeFronzo RA (September 2008). "Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus". Endocrine Practice. 14 (6): 782–790. doi:10.4158/ep.14.6.782. PMID 18996802.
Nair S, Wilding JP (January 2010). "Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus". The Journal of Clinical Endocrinology and Metabolism. 95 (1): 34–42. doi:10.1210/jc.2009-0473. PMID 19892839.
Bays H (March 2009). "From victim to ally: The kidney as an emerging target for the treatment of diabetes mellitus". Current Medical Research and Opinion. 25 (3): 671–681. doi:10.1185/03007990802710422. PMID 19232040.

dailymed.nlm.nih.gov

"Jardiance- empagliflozin tablet, film coated". DailyMed. 22 January 2020. Retrieved 10 February 2020.

ncbi.nlm.nih.gov

Anderson JE, Wright EE, Shaefer CF (February 2017). "Empagliflozin: Role in treatment options for patients with type 2 diabetes mellitus". Diabetes Therapy. 8 (1): 33–53. doi:10.1007/s13300-016-0211-x. PMC 5306110. PMID 27837465.

va.gov

pbm.va.gov

"Empagliflozin (Jardiance) National Drug Monograph" (PDF). VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives. Archived from the original (PDF) on 5 August 2019. Retrieved 13 August 2021.

web.archive.org

"Empagliflozin (Jardiance) National Drug Monograph" (PDF). VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives. Archived from the original (PDF) on 5 August 2019. Retrieved 13 August 2021.

who.int

"Obesity and overweight fact sheet" (PDF). World Health Organization.

worldcat.org

Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James; Verma, Subodh; Tsutsui, Hiroyuki (2020-10-08). "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure". New England Journal of Medicine. 383 (15): 1413–1424. doi:10.1056/NEJMoa2022190. ISSN 0028-4793. PMID 32865377.